“CU Lab’s Fruit-Fly Work Yields Patented Cancer Treatment” by Jeff Thomas. Link here: http://www.colorado.edu/asmagazine/2016/11/21/cu-labs-fruit-fly-work-yields-patented-cancer-treatment
SAB Member and Collaborator, Gail Eckhardt, Named Associate Dean and Inaugural Director of the Livestrong Cancer Institutes of the Dell Medical School, University of Texas at Austin
SuviCa is pleased to share the exciting news that SAB member and collaborator, Dr. Gail Eckhardt, has been named Associate Dean and Inaugural Director of the Livestrong Cancer Institutes of the Dell Medical School at the University of Texas at Austin. She will assume the position full time in January of 2017. Press release from […]
Research by Professor Tin Tin Su, SuviCa’s Co-Founder and CSO, and Dr. Shilpi Verghese, CU Boulder Post-Doctoral Fellow, Published in PLoS Biology
Research by Professor Tin Tin Su, SuviCa’s co-founder and CSO, and Dr. Shilpi Verghese, CU Boulder post-doctoral fellow, was published in PLoS Biology in an article titled “Drosophila Wnt and STAT Define Apoptosis-Resistant Epithelial Cells for Tissue Regeneration after Irradiation”. Article Here: http://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1002536
SuviCa’s SAB member, Paul Bunn, received ASCO’s David Karnofsky Memorial Award for his lung cancer work. See: https://am.asco.org/2016-david-karnofsky-memorial-award-bestowed-upon-dr-paul-bunn-jr and http://www.coloradocancerblogs.org/cu-cancer-centers-paul-bunn-jr-md-fasco-earns-asco-david-karnofsky-memorial-award/
Co-Founder and CSO, Dr. Tin Tin Su interviewed on Colorado Public Radio’s Colorado Matters in story titled “In the ‘Moonshot’ Against Cancer, Where Does Colorado Stand?” For full story, click here: https://www.cpr.org/news/story/moonshot-against-cancer-where-does-colorado-stand.
CU biotech start-up gets $1.5 million contract to develop head and neck cancer treatment – See more at: http://www.colorado.edu/news/releases/2015/10/15/cu-biotech-start-gets-15-million-contract-develop-head-and-neck-cancer-treatment
Please see new article by SuviCa scientists and advisory board members titled “Bouvardin is a Radiation Modulator with a Novel Mechanism of Action” (Stickel SA, et al. Radiat Res. 2015): http://www.ncbi.nlm.nih.gov/pubmed/26414509.
January, 2015: Congratulations to Drs. Raben and Jimeno who are co-author and senior author, respectively, on an article in Clinical Cancer Research that describes a Phase 1 study of a multi-target inhibitor in combination with chemo-radiation in patients with head and neck cancer. More information at http://www.ncbi.nlm.nih.gov/pubmed/25573383.
SuviCa, Inc. Awarded SBIR Phase 1 NCI Contract To Study Its Lead Molecules In Preclinical Models Of Head And Neck Cancer
September 24th, 2013: SuviCa, Inc., a private cancer drug discovery and development company that applies its proprietary screen to identify small molecule anticancer agents, announced today that it has been awarded a Small Business Innovation Research (SBIR) Phase 1 contract from the National Cancer Institute (NCI). Through the terms of the contract, SuviCa will discover […]
SuviCa is pleased to announce that it has been selected to present at the Rocky Mountain Life Science Investor & Partnering Conference to be held September 18-19 at the Ritz-Carlton Hotel in Denver, Colorado. For full story see: http://www.cobioscience.com/news-1/presenting-companies-announced.